Lu Qian, Ming-Qiang Cao, Ze-Xiong Feng, Cao Zou, Si-Jia Sun, Sheng-Da Hu
{"title":"壳聚糖止血垫可减少未受控制的高血压患者经桡动脉冠状动脉介入术后的血管并发症壳聚糖止血垫在CAG或PCI上的应用","authors":"Lu Qian, Ming-Qiang Cao, Ze-Xiong Feng, Cao Zou, Si-Jia Sun, Sheng-Da Hu","doi":"10.1155/2024/4819420","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> Vascular complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) are a major concern for revascularization therapies. In this study, we investigated whether the application of a chitosan-based hemostatic pad (HP) could ameliorate vascular complications after CAG or PCI procedures.</p>\n <p><b>Methods:</b> We retrospectively analyzed patients undergoing CAG or PCI in our cardiovascular center from January 2019 to December 2021. The incidence of total vascular complications including errhysis, large hematoma, pseudoaneurysm, radial artery occlusion (RAO), blister, and pain was recorded. Subgroup analyses of patients with a history of hypertension, patients with uncontrolled hypertension, and patients with controlled hypertension were performed.</p>\n <p><b>Results:</b> Our results demonstrated that the application of chitosan-based HP had no effect on vascular complications after CAG or PCI procedures (odds ratio [OR]: 1.03 (0.84–1.26), <i>p</i> = 0.80). Nevertheless, chitosan-based HP treatment markedly decreased the incidence of vascular complications in uncontrolled hypertensive patients (OR: 0.32 (0.11–0.95), <i>p</i> = 0.04), but not in hypertensive patients with controlled blood pressure (BP) (OR: 1.09 (0.88–1.35), <i>p</i> = 0.42).</p>\n <p><b>Conclusions:</b> Chitosan-based HP treatment could reduce the incidence of vascular complications in patients with uncontrolled hypertension. Nonetheless, applying chitosan-based HP treatment after CAG or PCI procedures is not recommendable for controlled hypertensive patients.</p>\n </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4819420","citationCount":"0","resultStr":"{\"title\":\"Chitosan-Based Hemostatic Pad Reduced Vascular Complications After Transradial Coronary Intervention in Uncontrolled Hypertensive Patients: Application of Chitosan-Based Hemostatic Pad on CAG or PCI\",\"authors\":\"Lu Qian, Ming-Qiang Cao, Ze-Xiong Feng, Cao Zou, Si-Jia Sun, Sheng-Da Hu\",\"doi\":\"10.1155/2024/4819420\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Background:</b> Vascular complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) are a major concern for revascularization therapies. In this study, we investigated whether the application of a chitosan-based hemostatic pad (HP) could ameliorate vascular complications after CAG or PCI procedures.</p>\\n <p><b>Methods:</b> We retrospectively analyzed patients undergoing CAG or PCI in our cardiovascular center from January 2019 to December 2021. The incidence of total vascular complications including errhysis, large hematoma, pseudoaneurysm, radial artery occlusion (RAO), blister, and pain was recorded. Subgroup analyses of patients with a history of hypertension, patients with uncontrolled hypertension, and patients with controlled hypertension were performed.</p>\\n <p><b>Results:</b> Our results demonstrated that the application of chitosan-based HP had no effect on vascular complications after CAG or PCI procedures (odds ratio [OR]: 1.03 (0.84–1.26), <i>p</i> = 0.80). Nevertheless, chitosan-based HP treatment markedly decreased the incidence of vascular complications in uncontrolled hypertensive patients (OR: 0.32 (0.11–0.95), <i>p</i> = 0.04), but not in hypertensive patients with controlled blood pressure (BP) (OR: 1.09 (0.88–1.35), <i>p</i> = 0.42).</p>\\n <p><b>Conclusions:</b> Chitosan-based HP treatment could reduce the incidence of vascular complications in patients with uncontrolled hypertension. Nonetheless, applying chitosan-based HP treatment after CAG or PCI procedures is not recommendable for controlled hypertensive patients.</p>\\n </div>\",\"PeriodicalId\":16329,\"journal\":{\"name\":\"Journal of interventional cardiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4819420\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of interventional cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/4819420\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of interventional cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/4819420","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:冠状动脉造影术(CAG)或经皮冠状动脉介入治疗(PCI)后的血管并发症是血管重建疗法的主要问题。在这项研究中,我们探讨了应用壳聚糖止血垫(HP)能否改善 CAG 或 PCI 术后的血管并发症。 方法:我们回顾性分析了2019年1月至2021年12月在我们心血管中心接受CAG或PCI手术的患者。记录了包括呃逆、大血肿、假性动脉瘤、桡动脉闭塞(RAO)、水泡和疼痛在内的全部血管并发症的发生率。对有高血压病史的患者、未控制的高血压患者和已控制的高血压患者进行了分组分析。 结果结果表明,应用壳聚糖 HP 对 CAG 或 PCI 术后的血管并发症没有影响(几率比 [OR]:1.03 (0.84-1.26), p = 0.80).然而,壳聚糖 HP 治疗显著降低了未控制的高血压患者的血管并发症发生率(OR:0.32 (0.11-0.95),p = 0.04),但未降低控制血压 (BP) 的高血压患者的血管并发症发生率(OR:1.09 (0.88-1.35),p = 0.42)。 结论基于壳聚糖的高血压治疗可降低未控制高血压患者血管并发症的发生率。不过,不建议已控制的高血压患者在 CAG 或 PCI 术后使用壳聚糖 HP 治疗。
Chitosan-Based Hemostatic Pad Reduced Vascular Complications After Transradial Coronary Intervention in Uncontrolled Hypertensive Patients: Application of Chitosan-Based Hemostatic Pad on CAG or PCI
Background: Vascular complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) are a major concern for revascularization therapies. In this study, we investigated whether the application of a chitosan-based hemostatic pad (HP) could ameliorate vascular complications after CAG or PCI procedures.
Methods: We retrospectively analyzed patients undergoing CAG or PCI in our cardiovascular center from January 2019 to December 2021. The incidence of total vascular complications including errhysis, large hematoma, pseudoaneurysm, radial artery occlusion (RAO), blister, and pain was recorded. Subgroup analyses of patients with a history of hypertension, patients with uncontrolled hypertension, and patients with controlled hypertension were performed.
Results: Our results demonstrated that the application of chitosan-based HP had no effect on vascular complications after CAG or PCI procedures (odds ratio [OR]: 1.03 (0.84–1.26), p = 0.80). Nevertheless, chitosan-based HP treatment markedly decreased the incidence of vascular complications in uncontrolled hypertensive patients (OR: 0.32 (0.11–0.95), p = 0.04), but not in hypertensive patients with controlled blood pressure (BP) (OR: 1.09 (0.88–1.35), p = 0.42).
Conclusions: Chitosan-based HP treatment could reduce the incidence of vascular complications in patients with uncontrolled hypertension. Nonetheless, applying chitosan-based HP treatment after CAG or PCI procedures is not recommendable for controlled hypertensive patients.
期刊介绍:
Journal of Interventional Cardiology is a peer-reviewed, Open Access journal that provides a forum for cardiologists determined to stay current in the diagnosis, investigation, and management of patients with cardiovascular disease and its associated complications. The journal publishes original research articles, review articles, and clinical studies focusing on new procedures and techniques in all major subject areas in the field, including:
Acute coronary syndrome
Coronary disease
Congenital heart diseases
Myocardial infarction
Peripheral arterial disease
Valvular heart disease
Cardiac hemodynamics and physiology
Haemostasis and thrombosis